Anavex Life Sciences Corp.

( )
AVXL PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
MRNAModerna, Inc. 0.14%283.800.0%$3957.11m
BNTXBioNTech SE 0.27%292.730.0%$1264.85m
NVAXNovavax, Inc. -3.05%176.2078.2%$838.17m
AMGNAmgen, Inc. 0.20%213.961.4%$652.89m
LGVNLongeveron Inc. 2.74%22.500.0%$529.43m
GILDGilead Sciences, Inc. -0.21%69.571.0%$514.09m
VRTXVertex Pharmaceuticals, Inc. 0.19%207.001.9%$454.95m
REGNRegeneron Pharmaceuticals, Inc. 0.10%654.702.7%$419.81m
ILMNIllumina, Inc. -0.26%375.003.3%$350.85m
SNSSSunesis Pharmaceuticals, Inc. 0.00%4.360.7%$304.78m
BIIBBiogen, Inc. -0.74%232.981.8%$295.76m
SGENSeagen Inc. 0.00%149.555.8%$157.99m
EXASEXACT Sciences Corp. 0.84%86.9818.0%$152.21m
INCYIncyte Corp. 0.00%67.332.4%$147.13m
TXG10X Genomics, Inc. 1.89%154.990.0%$140.09m

Company Profile

Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.